AbbVie Inc (ABBV)vsHeartflow, Inc. Common Stock (HTFL)
ABBV
AbbVie Inc
$203.89
+3.14%
HEALTHCARE · Cap: $351.47B
HTFL
Heartflow, Inc. Common Stock
$29.53
-3.34%
HEALTHCARE · Cap: $2.61B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 34643% more annual revenue ($61.16B vs $176.03M). ABBV leads profitability with a 6.9% profit margin vs -66.3%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
HTFL
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-24.9%
Fair Value
$163.42
Current Price
$203.89
$40.47 premium
Intrinsic value data unavailable for HTFL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Revenue surging 40.5% year-over-year
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Trading at 8.4x book value
0.0% earnings growth
ROE of -111.4% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.47 suggests the stock is reasonably priced for its growth.
Bull Case : HTFL
The strongest argument for HTFL centers on Revenue Growth. Revenue growth of 40.5% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 84.2x leaves little room for execution misses.
Bear Case : HTFL
The primary concerns for HTFL are Price/Book, EPS Growth, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while HTFL is a hypergrowth play — different risk/reward profiles.
HTFL is growing revenue faster at 40.5% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 30/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Heartflow, Inc. Common Stock
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases globally. The company is headquartered in Mountain View, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?